Literature DB >> 19657979

Feasibility study of lamellar keratoplasty in a murine model.

Ting Huang1, Stephen R Planck, James T Rosenbaum, Ellen J Lee.   

Abstract

PURPOSE: In contrast to penetrating keratoplasty (PK), the donor cornea in lamellar keratoplasty (LK) remains separated from the host aqueous humor. There is debate about relative merits of each approach, but experimental comparisons have never been performed in animal models. Therefore, the authors developed a murine LK model.
METHODS: For allogeneic PK and LK surgeries, corneas of C57BL/6 mice were transplanted to BALB/c mice, assessed by slit lamp, and scored for opacity, edema, and neovascularization up to 46 d post-transplantation. Additional PK or LK surgeries were performed for histological assessment.
RESULTS: Graft rejection rate was less in LK vs. PK (69.2 vs. 100%), as was neovascularization (84.6 vs. 100%). In LK, inflammatory cells infiltrated primarily the button; in PK, heavier infiltration was observed throughout the cornea.
CONCLUSIONS: This study demonstrates the feasibility of LK in mice and presents data suggesting that the inflammatory response in LK differs from that in PK.

Entities:  

Mesh:

Year:  2009        PMID: 19657979      PMCID: PMC4049114          DOI: 10.1080/09273940902802683

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  26 in total

Review 1.  Anterior chamber-associated immune deviation.

Authors:  J Y Niederkorn
Journal:  Chem Immunol       Date:  1999

2.  Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59.

Authors:  J H Sohn; H J Kaplan; H J Suk; P S Bora; N S Bora
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-12       Impact factor: 4.799

Review 3.  Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology.

Authors:  Claus Cursiefen; Lu Chen; M Reza Dana; J Wayne Streilein
Journal:  Cornea       Date:  2003-04       Impact factor: 2.651

Review 4.  The immune privilege of corneal grafts.

Authors:  Jerry Y Niederkorn
Journal:  J Leukoc Biol       Date:  2003-08       Impact factor: 4.962

Review 5.  The evolution of lamellar grafting techniques over twenty-five years.

Authors:  M A Terry
Journal:  Cornea       Date:  2000-09       Impact factor: 2.651

6.  Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins.

Authors:  J H Sohn; H J Kaplan; H J Suk; P S Bora; N S Bora
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-10       Impact factor: 4.799

7.  Absence of blood and lymphatic vessels in the developing human cornea.

Authors:  Claus Cursiefen; Carmen Rummelt; Anselm Jünemann; Christian Vorwerk; Winfried Neuhuber; Friedrich E Kruse; Falk Schroedl
Journal:  Cornea       Date:  2006-07       Impact factor: 2.651

8.  Role of tumor necrosis factor receptor expression in anterior chamber-associated immune deviation (ACAID) and corneal allograft survival.

Authors:  Jerry Y Niederkorn; Elizabeth Mayhew; Jessamee Mellon; Sushma Hegde
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-08       Impact factor: 4.799

9.  Fate of MHC-matched corneal allografts in Th1-deficient hosts.

Authors:  Sylvia L Hargrave; Christina Hay; Jessamee Mellon; Elizabeth Mayhew; Jerry Y Niederkorn
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-04       Impact factor: 4.799

10.  Effect of metalloprotease inhibitors on corneal allograft survival.

Authors:  Patrick M Stuart; Fan Pan; Xiaotang Yin; Zdenka Haskova; Stacey Plambeck; Thomas A Ferguson
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-04       Impact factor: 4.799

View more
  1 in total

1.  Tectonic lamellar keratoplasty with acellular corneal stroma in high-risk corneal transplantation.

Authors:  Naiyang Li; Xiaoran Wang; Pengxia Wan; Minghai Huang; Zheng Wu; Xuanwei Liang; Ying Liu; Jian Ge; Junqi Huang; Zhichong Wang
Journal:  Mol Vis       Date:  2011-07-15       Impact factor: 2.367

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.